VestGen Advisors’s Arcus Biosciences RCUS Stock Holding History

VestGen Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-27,152	Closed	-$647K	–	1094
2025 Q4	$647K	Buy	+27,152	New	+$554K	0.03%	432

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VestGen Advisors's RCUS Position: Q1 2026 in Review

VestGen Advisors sold out of Arcus Biosciences (RCUS) in Q1 2026, closing a stake of 27,152 shares — an estimated $647K sold.

VestGen Advisors first reported a position in RCUS in Q4 2025 and held it in 1 quarter. The position peaked at $647K in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

VestGen Advisors reported no remaining Arcus Biosciences position as of Q1 2026 after selling out during the quarter.
VestGen Advisors sold 27,152 Arcus Biosciences shares in Q1 2026, an estimated $647K.
VestGen Advisors first reported a position in Arcus Biosciences in Q4 2025 and held it in 1 quarter.
VestGen Advisors's Arcus Biosciences position peaked at $647K in Q4 2025.
210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on VestGen Advisors's 13F filing for Q1 2026, filed 14 May 2026.